You are here

  • Home
  • Archive
  • Volume 6, Issue 2
  • Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Article metrics

Article menu

Download PDFPDF

Psoriatic arthritis
Original research
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

 

Online download statistics by month:

Online download statistics by month: July 2020 to March 2024

AbstractFullPdf
Jul 2020394384170
Aug 202016015997
Sep 2020807569
Oct 2020777633
Nov 2020797747
Dec 2020767425
Jan 2021888437
Feb 20211079739
Mar 202111611131
Apr 20211039840
May 2021949332
Jun 2021837941
Jul 2021555338
Aug 2021787628
Sep 202111110747
Oct 202112011960
Nov 2021575337
Dec 2021766931
Jan 2022696425
Feb 2022656427
Mar 2022838132
Apr 2022747041
May 2022929334
Jun 2022737621
Jul 2022727333
Aug 2022757424
Sep 2022646129
Oct 2022666618
Nov 2022979526
Dec 2022434114
Jan 2023747436
Feb 202372679
Mar 2023767322
Apr 2023616023
May 2023383822
Jun 2023464423
Jul 2023403619
Aug 202325257
Sep 2023252512
Oct 2023504919
Nov 2023373616
Dec 2023343319
Jan 2024161615
Feb 2024615524
Mar 2024434181
Total352534141573